

Electronic Acknowledgement Receipt

EFS ID:	4416468
Application Number:	10699517
International Application Number:	
Confirmation Number:	8113
Title of Invention:	Prevention and treatment of synucleinopathic disease
First Named Inventor/Applicant Name:	Dale B. Schenk
Customer Number:	20350
Filer:	Rosemarie L. Celli/Tina Trieu
Filer Authorized By:	Rosemarie L. Celli
Attorney Docket Number:	015270-008920US
Receipt Date:	08-DEC-2008
Filing Date:	31-OCT-2003
Time Stamp:	18:50:35
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 180
RAM confirmation Number	4138
Deposit Account	201430
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		015270-008920US_SIDS_12-08-2008.PDF	230662 4c5a899eab2e70d7cea3e1e17230e1c7faa6dae8	yes	5
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Information Disclosure Statement Letter		1	3	
	Information Disclosure Statement (IDS) Filed (SB/08)		4	5	
Warnings:					
Information:					
2	Foreign Reference	222-WO08103472A2.pdf	6759680 2f58789b7bd7232f5384941ccfd86b8f5d7ab9a7	no	135
Warnings:					
Information:					
3	Foreign Reference	235-WO03000714A2.pdf	595533 2f07f10569f7742a4df8c043c1256f8adf01632c	no	12
Warnings:					
Information:					
4	Foreign Reference	236-WO03000714A3.pdf	119865 a4f6c14ac110587643b66c08ca2a5aaa9a0a425	no	2
Warnings:					
Information:					
5	Foreign Reference	227-WO0160794A2.pdf	2081191 070be659c8b29d6c2a33e4606165e8e17af466bb	no	55
Warnings:					
Information:					
6	Foreign Reference	228-WO0160794A3.pdf	136589 85053567dae5febec560236f91ea33140f2e9d4c	no	3
Warnings:					
Information:					

7	NPL Documents	226-AndersonJBC281-40-29739_2006.pdf	2681006	no	14
			d75c3704dbfacaf49b62081d18a6a4ff480bc36a		
Warnings:					
Information:					
8	NPL Documents	224-CHILCOTE_ComparisonofalphasynucleinAbstract.pdf	73698	no	2
			ea63e81302f1b983c3e18dd240f385c033a46f81		
Warnings:					
Information:					
9	NPL Documents	237-EP037830083-3_EuroSupplSearch.pdf	407998	no	11
			417b9e268b627042c1829959d6593b641e06915e		
Warnings:					
Information:					
10	NPL Documents	238-EP05814041-9_SupplEuroSearchReport.pdf	1237320	no	26
			e88499f38e0dc91da9c6bbcee98d22df601ad057		
Warnings:					
Information:					
11	NPL Documents	229-Hashimoto_BetaSynucleinInhibitsAlpha.PDF	568920	no	6
			93e76b7910d1d5a15f32cc8d2692df33c689db83		
Warnings:					
Information:					
12	NPL Documents	233-Heiser_InhibitionofHuntingtinFibrillogenesis_2000.PDF	374433	no	3
			25e3ab0e32c5e41625c5465295368b422019e0c4		
Warnings:					
Information:					
13	NPL Documents	232-Lecerf_HumanSingleChainFV_2001.PDF	319915	no	3
			0e5d8e4cbc3c0a32bee119c37a1df806e63995b9		
Warnings:					
Information:					
14	NPL Documents	225-Lee_TruncatedAlphaAbstract.pdf	32849	no	2
			5f0afb9b93d19cf4cd91fc99d9eeb8c542bc84b1		
Warnings:					
Information:					
15	NPL Documents	234-Rochet_InhibitionofFibrillization_2000.PDF	446278	no	4
			772cd4c3a0e17e4933a68f085942988b5a0c8b9f		
Warnings:					
Information:					

16	NPL Documents	223- TofarisJBC278-45-44405_2003. pdf	336461 c594bc2a7226f9e6db1ef2910533a93b3c1e2fce	no	7
Warnings:					
Information:					
17	NPL Documents	231- Wanker_ProtienAggregationin HuntingtonsandParkinsonsDis- 2000.PDF	354183 9ad64c078a1758985f475becda082539d45e5593	no	3
Warnings:					
Information:					
18	NPL Documents	230- Windsch_DevelopmentOfANe wTreatment_2002.PDF	317607 6894b8cfe5580bd47bc21f5ac7a8393d0aa8f14	no	4
Warnings:					
Information:					
19	Fee Worksheet (PTO-06)	fee-info.pdf	30130 5c0a36c0843dfd0235f085bb584469c96d867dcf	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			17104318		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					